Saturday, February 16, 2019

National Patient Safety Agency warning over low molecular weight heparins

The National Patient Safety Agency has warned that a patient’s weight must be known and documented before a low molecular weight heparin (LMWH) is...

National Pharmacy Association concerns about GPhC rolling register

The National Pharmacy Association has warned that a rolling register allowing pharmacists to sign up to the GPhC at any time during the year...

Novo Nordisk’s decision to drop Mixtard 30 encounters fierce opposition

An online petition against drug manufacturer Novo Nordisk’s decision to discontinue its human insulin Mixtard 30 in the UK at the end of the...

Actavis indicates commitment to growing OTC markets with brand investment

Actavis has indicated its commitment to growing OTC markets by investing in two of its 17 brands. The manufacturer better known for its generics business...

U.S. drug reviewers raise concerns about epilepsy treatment Potiga

U.S. drug reviewers are concerned about urinary retention seen in some patients treated with an experimental epilepsy medicine from GlaxoSmithKline and Valeant Pharmaceuticals according...

Asthma inhalers may be linked to prostate cancer says Australian study

An Australian study has suggested that asthma sufferers who regularly use an inhaler to ease their symptoms could be at greater risk of prostate...

NHS highlight increase in dispensed prescriptions in 2009

Statistics from the NHS Information Centre has highlighted that prescriptions dispensed in the community in 2009 were up 5% on the year before. The increase...

Sanofi-Aventis faces weeks of haggling over deal to buy U.S. biotech firm Genzyme

Paris-based drug maker Sanofi-Aventis faces weeks of haggling to get a deal on buying U.S. biotech firm Genzyme as the two parties appear...

Angiomax granted one-year interim patent extension

Medicines Co has announced that the U.S. Patent and Trademark Office has granted a one-year interim patent extension for its lead drug Angiomax. A U.S....

GPhC will not subject pharmacists to unnecessary disciplinary procedures, says chief executive

The General Pharmaceutical Council the future pharmacy regulator will not put pharmacists through disciplinary processes unnecessarily according to chief executive Duncan Rudkin. Rudkin maintained that...